Global Picato Gel (Ingenol Mebutate) Market Size By Type (Type I, Type II), By Application (Actinic Keratosis, Keratosis), By Region, And Segment Forecasts, 2023 to 2032

The Global Picato Gel (Ingenol Mebutate) Market was valued at USD 320 million in 2023 and is projected to reach USD 510 million by 2031, expanding at a CAGR of 6.0% during the forecast period of 2023 to 2031. Picato Gel, a topical medication derived from the sap of the Euphorbia peplus plant, is primarily used for the treatment of actinic keratosis (AK), a pre-cancerous skin condition. The market growth is driven by increasing incidences of AK due to rising UV exposure, expanding elderly population prone to skin disorders, and heightened awareness about early skin cancer prevention. Demand is also supported by dermatologists' preference for short-duration topical therapies and the growing interest in plant-based pharmaceuticals.

Drivers:

Rising Incidence of Actinic Keratosis:

The increasing prevalence of AK, particularly in regions with high UV exposure such as North America, Australia, and parts of Europe, is a primary growth driver. Picato Gel offers a convenient, rapid treatment option, fueling its adoption.

Shift Towards Minimally Invasive Dermatological Therapies:

Picato Gel’s short treatment duration (2–3 days) and topical nature align with the rising demand for non-invasive skin treatments. This benefits both patient adherence and treatment outcomes.

Growing Geriatric Population:

Aging populations, particularly in developed countries, are more susceptible to skin disorders including AK. This demographic shift is significantly boosting demand for effective topical treatments like Picato Gel.

Restraints:

Market Withdrawal in Some Regions:

Regulatory concerns related to the safety of Picato Gel—particularly reports of skin cancer risks—have led to its market withdrawal in regions like the EU, which limits global market expansion.

Availability of Alternative Therapies:

The presence of alternative treatments such as imiquimod, fluorouracil, and diclofenac reduces the exclusive reliance on Picato Gel, constraining its market share.

Opportunity:

Development of Next-Generation Formulations:

R&D in synthetic and plant-based derivatives with improved safety profiles presents a strong opportunity for revitalizing the Picato Gel market or its next-generation analogs.

Emerging Markets and Teledermatology Growth:

Rising demand for dermatological care in emerging economies and the expanding reach of teledermatology open new distribution and education channels for topical AK treatments.

Market by System Type Insights:

By system type, 0.015% concentration for face and scalp treatment dominated the market in 2023. This segment is favored due to its efficacy and reduced treatment time. Meanwhile, the 0.05% concentration for trunk and extremities is gaining traction, particularly in older populations with multiple lesion sites. Innovations in delivery systems and product packaging are enhancing patient experience and compliance.

Market by End-Use Insights:

Hospitals and Dermatology Clinics accounted for the largest share in 2023, due to increased AK diagnosis and prescription rates by dermatologists. However, the online pharmacy segment is witnessing the fastest growth owing to growing direct-to-consumer interest and the convenience of e-health services, especially post-COVID-19.

Market by Regional Insights:

North America led the market in 2023, owing to a high prevalence of actinic keratosis, greater awareness, and favorable reimbursement policies. However, Asia-Pacific is expected to witness the fastest CAGR during the forecast period, driven by increasing skin disorder diagnoses, urbanization, and improving healthcare infrastructure. Regions like Latin America are emerging as lucrative markets due to rising healthcare access and public education on skin cancer.

Competitive Scenario:

Key players in the Picato Gel (Ingenol Mebutate) market include LEO Pharma, Sun Pharmaceutical Industries, Taro Pharmaceutical Industries, Perrigo Company plc, and various generic manufacturers. Strategies include regulatory re-approvals, development of safer analogs, and strategic partnerships with dermatology-focused telehealth providers.

Key Market Developments:

In 2023, Sun Pharma initiated clinical trials for an ingenol-based gel with modified formulation to reduce side effects.

In 2024, Perrigo relaunched an OTC dermatology division targeting AK and other pre-cancerous lesions with plant-based treatments.

In 2025, LEO Pharma announced partnerships with AI-powered teledermatology platforms to enhance outreach and patient support for AK treatment.

Scope of Work – Global Picato Gel (Ingenol Mebutate) Market

FAQs:

1) What is the current market size of the Global Picato Gel (Ingenol Mebutate) Market?

The market size was valued at USD 320 million in 2023.

2) What is the major growth driver of the Global Picato Gel (Ingenol Mebutate) Market?

The major growth driver is the rising prevalence of actinic keratosis and increasing demand for fast-acting topical treatments.

3) Which is the largest region during the forecast period in the Global Picato Gel (Ingenol Mebutate) Market?

North America is the largest regional market due to high AK incidence and robust dermatology infrastructure.

4) Which segment accounted for the largest market share in Global Picato Gel (Ingenol Mebutate) Market?

The 0.015% concentration for face and scalp treatment segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Picato Gel (Ingenol Mebutate) Market?

Key players include LEO Pharma, Sun Pharmaceutical Industries, Taro Pharmaceutical Industries, and Perrigo Company plc.